Get started
Author

Li Zhang

Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis
2013 · Mian Xi, Li Zhang, et al. · PLoS ONE · 149
PDF
Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial
2023 · Yujia Zhu, Jing Wen, et al. · The Lancet Oncology · 111
Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal Cancer
2018 · Mian Xi, Yadi Yang, et al. · Annals of Surgery · 95
Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial
2021 · Shiliang Liu, Liling Luo, et al. · Nature Communications · 53
PDF
Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes
2020 · Hui Xu, Maosheng Lin, et al. · The Oncologist · 40
PDF
Propensity score-based comparison of survival and radiation pneumonitis after definitive chemoradiation for esophageal cancer: Intensity-modulated radiotherapy versus three-dimensional conformal radiotherapy
2020 · Kaiqi Lan, Jinhan Zhu, et al. · Radiotherapy and Oncology · 28
Comparing docetaxel plus cisplatin versus fluorouracil plus cisplatin in esophageal squamous cell carcinoma treated with neoadjuvant chemoradiotherapy
2017 · Mian Xi, Peng Zhang, et al. · Japanese Journal of Clinical Oncology · 20
Clinicopathologic Characteristics and Prognosis of Tongue Squamous Cell Carcinoma in Patients with and without a History of Radiation for Nasopharyngeal Carcinoma: A Matched Case-Control Study
2016 · Peng Zhang, Li Zhang, et al. · Cancer Research and Treatment · 20
PDF
Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case–control study
2015 · Shi-Liang Liu, Hong Yang, et al. · Radiotherapy and Oncology · 17
Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance Strategies
2018 · Sha Zhou, Shiliang Liu, et al. · Annals of Surgical Oncology · 16
Prognostic Factors and Survival in Patients with Radiation-Related Second Malignant Neoplasms Following Radiotherapy for Nasopharyngeal Carcinoma
2013 · Mian Xi, Shi-Liang Liu, et al. · PLoS ONE · 14
PDF
Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trial
2024 · Ruixi Wang, Yihong Ling, et al. · EClinicalMedicine · 13
Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
2024 · Lanlan Pang, Yihua Huang, et al. · Clinical Cancer Research · 10
PDF
Efficacy and Dose-Response Relationship of Stereotactic Body Radiotherapy for Abdominal Lymph Node Metastases from Hepatocellular Carcinoma
2023 · Yuting Wang, Qiaoqiao Li, et al. · The Oncologist · 9
PDF
Modeling the risk of radiation pneumonitis in esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
2021 · Kaiqi Lan, Cheng Xu, et al. · Esophagus · 9
PDF
Prognostic significance of PET/CT and its association with immuno-genomic profiling in oesophageal squamous cell carcinoma treated with immunotherapy plus chemoradiotherapy: results from a phase II study
2024 · Ruixi Wang, Shiliang Liu, et al. · British Journal of Cancer · 8
PDF
Failure pattern of elective nodal irradiation for esophageal squamous cell cancer treated with neoadjuvant chemoradiotherapy
2018 · Sha Zhou, Li Zhang, et al. · Japanese Journal of Clinical Oncology · 5
Assessing the role of volumetric‐modulated arc therapy in hepatocellular carcinoma
2013 · Mian Xi, Li Zhang, et al. · Journal of Applied Clinical Medical Physics · 4
PDF
Multi-omic analysis and overall survival update of phase II TRIDENT study: Durvalumab plus olaparib in extensive-stage small-cell lung cancer (ES-SCLC).
2025 · Yuanyuan Zhao, Yan Huang, et al. · Journal of Clinical Oncology · 2
Anti-LAG-3 antibody LBL-007 in combination with anti-PD-1 antibody tislelizumab with or without chemotherapy in patients with advanced nasopharyngeal cancer and other malignant tumors: A phase Ib/II dose escalation/expansion study.
2024 · Yunpeng Yang, Yu Chen, et al. · Journal of Clinical Oncology · 1
PDF
Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
2024 · Lanlan Pang, Yihua Huang, et al.
Supplementary Figure 1 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
2024 · Lanlan Pang, Yihua Huang, et al.
Supplementary Table 3 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
2024 · Lanlan Pang, Yihua Huang, et al.
PDF
Supplementary Table 2 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
2024 · Lanlan Pang, Yihua Huang, et al.
Supplementary Figure 4 from Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
2024 · Lanlan Pang, Yihua Huang, et al.
Works count: 45
Citation count: 624
H-index: 12
I10-index: 13
Year
Topic
Type